Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CRISPR
Biotech
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
CRISPR Tx reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310.
Nick Paul Taylor
May 7, 2025 10:00am
It's curtain close for Spotlight: Gene editing biotech shutters
Feb 19, 2025 4:28pm
Intellia cuts 27% of staff as it takes ax to pipeline
Jan 10, 2025 4:00am
Gene editor Scribe slims down workforce as it readies for clinic
Jan 8, 2025 5:33pm
Intellia, Alnylam post data on contrasting cardiomyopathy ideas
Nov 18, 2024 7:40am
Beam hits hemoglobin goal in first base editing clinical data
Nov 5, 2024 9:00am
